Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Benitec Biopharma Limited (BNTC : NSDQ)

• Company Description    Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $12.78 Daily Weekly Monthly 20 Day Moving Average: 230,634 shares Shares Outstanding: 26.25 (millions) Market Capitalization: $335.48 (millions) Beta: 0.37 52 Week High: $17.15 52 Week Low: $7.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.72% -22.47% 12 Week -7.05% -21.56% Year To Date 1.19% 2.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3940 Trust Way - Hayward,CA 94545 USA ph: 510-780-0819 fax: 61 (0)3 9966-9923 ikoffler@lifesciadvisors.com http://www.benitec.com

• General Corporate Information    Officers Jerel Banks - Chief Executive Officer; Director Megan Boston - Director J. Kevin Buchi - Director Peter Francis - Director Edward Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 08205P209 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/25/25 Share - Related Items Shares Outstanding: 26.25 Most Recent Split Date: 7.00 (0.06:1) Beta: 0.37 Market Capitalization: $335.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/25/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.07 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 85.37% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -38.26 12/31/24 - -44.61 ROA 06/30/25 - - 03/31/25 - -35.71 12/31/24 - -41.25 Current Ratio 06/30/25 - - 03/31/25 - 14.80 12/31/24 - 25.48 Quick Ratio 06/30/25 - - 03/31/25 - 14.80 12/31/24 - 25.48 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.16 12/31/24 - 3.27 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.62 12/31/24 - 0.00

Powered by Zacks Investment Research ©